Cardiovascular and psychiatric risk profile and patterns of use in patients starting anti-obesity drugs

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 7, 2009, Pages 631-638

  Willemen, Marjolein J C ^a,b   Mantel Teeuwisse, Aukje K ^a,b   Straus, Sabine M J M ^b   Leufkens, Hubert G M ^a,b   Egberts, Antoine C G ^a,c   Sturkenboom, Miriam C J M ^d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Benefit risk assessment; Medicines; Obesity; Pharmacovigilance

Indexed keywords

ANTIOBESITY AGENT; DEXFENFLURAMINE; FENFLURAMINE; MAZINDOL; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; ANGINA PECTORIS; ANXIETY DISORDER; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEPRESSION; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GENERAL PRACTICE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OBESITY; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 69049111139     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1759     Document Type: Article

References (27)

1. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348(17): 1625-1638.
2. Bergström A, Pisani P, Tenet V, et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001; 91(3): 421-430.
3. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006; 5(4): 295-309.
4. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335(9): 609-616.
5. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337(9): 581-588.
6. Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998; 339(11): 719-724.
7. Ioannides-Demos LL, Proietto J, Tonkin AM, et al. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006; 29(4): 277-302.
8. Diet drug Acomplia/Zimulti dealt blow as FDA panel says keep it off U.S. market. Available from URL: http://www.acompliareport.com/News/ news-061807.htm [Accessed 2008 June 17].
9. Sanofi-Aventis. Press-release. Available from URL: http://www.sanofiaventis. com/press/ppc_17004.asp#3 [Accessed 2008 June 17].
10. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008; 299(13): 1547-1560.
11. WHO Collaborating Centre for Drug Statistics Methodology. Complete ATC index 2008 [online]. Available from URL: http://www.whocc.no/atcddd/ [Accessed 2008 Nov 11].
12. Vlug AE, van der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999; 38(4-5): 339-344.
13. van der Lei J, Duisterhout JS, Westerhof HP, et al. The introduction of computer-based patient records in the Netherlands. Ann Intern Med 1993; 119(10): 1036-1041.
14. Willemen MJ, Mantel-Teeuwisse AK, Straus SJ, et al. Psychiatric and cardiovascular co-morbidities in patients with diabetes mellitus starting anti-obesity drug. Obesity (Silver Spring) 2008; 16(10): 2331-2335.
15. Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med 2003; 163(17): 2058-2065.
16. Onyike CU, Crum RM, Lee HB, et al. Is obesity associated with major depression? Results from the third National Health and Nutrition Examination Survey. Am J Epidemiol 2003; 158(12): 1139-1147.
17. Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity (Silver Spring) 2007; 15(11): 2712-2722.
18. Bouvy ML, Egberts TC. Consequences of a change in reimbursement status on prescription patterns. Eur J Clin Pharmacol 2000; 56(6-7): 511-512.
19. Stolk P, Schneeweiss S, Leufkens HG, et al. Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives. Contraception 2008; 78(5): 399-404.
20. Blanck HM, Serdula MK, Gillespie C, et al. Use of nonprescription dietary supplements for weight loss is common among Americans. J Am Diet Assoc 2007; 107(3): 441-447.
21. Mackenbach JP, Stirbu I, Roskam AJ, et al. Socioeconomic inequalities in health in 22 European countries. N Engl J Med 2008; 358(23): 2468-2481.
22. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368(9548): 1660-1672.
23. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295(7): 761-775.
24. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365(9468): 1389-1397.
25. Després JP, Golay A, Sjöström L, et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353(20): 2121-2134.
26. Rimonabant. European suspension of marketing authorisation. Drug Saf Update 2008; 1(10): 2-4.
27. Endocrine and Metabolic Drugs Advisory Committee. Rimonabant Briefing Document. Food And Drug Administration, 2007: 1-88. Available from: http://www.fda.gov/ohrms/dockets/AC/07/briefing/ 2007-4306b1-fda-backgrounder.pdf [accessed 2009 April 20]